Colorectal Cancer Screening: What You Need to Know

Colorectal cancer is the second leading cause of cancer death in the United States for men and women combined. The remarkable fact about this cancer is that it is almost entirely preventable through appropriate screening. Most colorectal cancers develop slowly from benign polyps over a period of years or decades. Screening detects these polyps before they become cancerous and removes them, or identifies cancer at its earliest and most treatable stage. Multiple effective colorectal cancer screening methods are available. Colonoscopy is the most comprehensive, directly visualizing the entire colon and allowing immediate removal of any polyps found. It is performed every ten years in average-risk individuals with a normal result. Flexible sigmoidoscopy examines only the lower portion of the colon and is performed every five years. High-sensitivity guaiac-based fecal occult blood tests and fecal immunochemical tests detect blood in the stool and are performed annually. Stool DNA tests such as Cologuard detect blood and abnormal DNA from polyps and cancers and are performed every one to three years. Current guidelines recommend colorectal cancer screening beginning at age 45 for all average-risk adults. Earlier and more frequent screening is recommended for individuals at higher risk, including those with a personal or family history of colorectal cancer or adenomatous polyps, personal history of inflammatory bowel disease, and certain inherited genetic conditions. African Americans may benefit from beginning screening at 45, as they have higher incidence and mortality rates. For patients managing conditions related to colorectal health and needing prescription support, accessible pharmacy care is available through https://www.amoxilcompharm.com/. Despite the clear evidence of benefit, colorectal cancer screening remains underutilized. Barriers include concerns about the preparation for colonoscopy, fear of embarrassment, financial costs, and underestimation of personal risk. Stool-based tests offer a non-invasive alternative for patients who decline colonoscopy. Any positive result on a stool-based test requires follow-up colonoscopy. Regular screening is the single most effective measure for reducing colorectal cancer mortality. For comprehensive colorectal cancer screening information and cancer prevention resources, visit https://amoxicillina.online/ for evidence-based patient guidance.